The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial

[1]  Stephan von Haehling,et al.  Cachexia as a major underestimated and unmet medical need: facts and numbers , 2010, Journal of cachexia, sarcopenia and muscle.

[2]  S. Anker,et al.  Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle , 2010, Journal of cachexia, sarcopenia and muscle.

[3]  A. Jette,et al.  Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.

[4]  W. Evans,et al.  Skeletal muscle loss: cachexia, sarcopenia, and inactivity. , 2010, The American journal of clinical nutrition.

[5]  Ramesh Narayanan,et al.  Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. , 2009, Journal of medicinal chemistry.

[6]  Shalender Bhasin,et al.  Tests of Muscle Strength and Physical Function: Reliability and Discrimination of Performance in Younger and Older Men and Older Men with Mobility Limitations , 2008, Journal of the American Geriatrics Society.

[7]  B. Tan,et al.  Cachexia: prevalence and impact in medicine , 2008, Current opinion in clinical nutrition and metabolic care.

[8]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[9]  A. Guay,et al.  The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. , 2007, The journal of sexual medicine.

[10]  M. McLaughlin,et al.  Why men's hearts break: cardiovascular effects of sex steroids. , 2007, Endocrinology and metabolism clinics of North America.

[11]  Walter R Frontera,et al.  Is stair climb power a clinically relevant measure of leg power impairments in at-risk older adults? , 2007, Archives of physical medicine and rehabilitation.

[12]  Jacqueline A Pugh,et al.  Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. , 2007, Archives of internal medicine.

[13]  B. Lunenfeld.  Testosterone deficiency and the metabolic syndrome , 2007, The aging male : the official journal of the International Society for the Study of the Aging Male.

[14]  A. Sañudo,et al.  Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[15]  Frederick C W Wu,et al.  Drug Insight: testosterone preparations , 2006, Nature Clinical Practice Urology.

[16]  J. Dalton,et al.  Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands , 2006, Pharmaceutical Research.

[17]  L. Groop,et al.  Long‐term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance , 2006, Journal of internal medicine.

[18]  Shalender Bhasin,et al.  Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[19]  Duane D. Miller,et al.  In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. , 2005, Endocrinology.

[20]  Duane D. Miller,et al.  The Para Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides Is a Major Structural Determinant of in Vivo Disposition and Activity of Selective Androgen Receptor Modulators , 2005, Journal of Pharmacology and Experimental Therapeutics.

[21]  F. López‐Soriano,et al.  Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. , 2005, The international journal of biochemistry & cell biology.

[22]  K. Jamerson.  Preventing chronic kidney disease in special populations. , 2005, American journal of hypertension.

[23]  S. Borst.  Interventions for sarcopenia and muscle weakness in older people. , 2004, Age and ageing.

[24]  Duane D. Miller,et al.  A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. , 2004, Journal of medicinal chemistry.

[25]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[26]  Hosam K Kamel,et al.  Sarcopenia and aging. , 2003, Nutrition reviews.

[27]  W. Frontera,et al.  Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. , 2002, The American journal of clinical nutrition.

[28]  W. Mitch,et al.  Mechanisms activated by kidney disease and the loss of muscle mass. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  V. Baracos.  Management of muscle wasting in cancer‐associated cachexia , 2001, Cancer.

[30]  Ack,et al.  LOWER-EXTREMITY FUNCTION IN PERSONS OVER THE AGE OF 70 YEARS AS A PREDICTOR OF SUBSEQUENT DISABILITY , 2001 .

[31]  R. Roubenoff.  Sarcopenia and its implications for the elderly , 2000, European journal of clinical nutrition.

[32]  A. Negro-Vilar.  Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.

[33]  S. Heymsfield,et al.  Epidemiology of sarcopenia among the elderly in New Mexico. , 1998, American journal of epidemiology.

[34]  E. Bruera.  ABC of palliative care: Anorexia, cachexia, and nutrition , 1997 .

[35]  M. Fallon,et al.  ABC of Palliative Care , 1997 .

[36]  N. Ancy,et al.  The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. , 1996 .

[37]  R. Casaburi,et al.  The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. , 1996, The New England journal of medicine.

[38]  R B Wallace,et al.  Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. , 1995, The New England journal of medicine.

[39]  P. Thompson,et al.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. , 1989, JAMA.

[40]  D. Large,et al.  WHICH TESTOSTERONE REPLACEMENT THERAPY? , 1984, Clinical endocrinology.

[41]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[42]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[43]  D. Ferriman,et al.  Clinical assessment of body hair growth in women. , 1961, The Journal of clinical endocrinology and metabolism.